Efficacy and security starting safinamide treatment with 100 mg/day in PD
Objective: Evaluating the efficacy and security starting safinamide treatment with 100 mg/day in PD Background: Dopaminergic treatment has been useful in PD. Other neurotransmission mechanisms…Dysphagia predicts poor outcome in late-stage Parkinson’s disease
Objective: to evaluate the clinical progression and prognostic factors of a late-stage PD (LSPD) population. Background: Parkinson’s disease (PD) disability milestones emerge in an exponential…Deep brain stimulation and its efficacy using microelectrode recording
Objective: To render the significance of microelectrode recording and elucidate its prognostic role in response to STNDBS. Background: Studies[1]-[9] have correlated local field potential(LFP) and…The effects of deep brain stimulation of the pedunculopontine nucleus on cognition in Parkinson’s disease and Progressive Supranuclear Palsy
Objective: To investigate the effects of deep brain stimulation (DBS) of the pedunculopontine nucleus (PPN) on different cognitive domains for Parkinson’s disease (PD) and progressive…Underserved Patient Access to Movement Disorders Care: Experience from a Tertiary Academic Referral Center
Objective: To explore geographical and clinic-demographical profile of underserved patients in Florida diagnosed with movement disorders. Background: Movement disorders are complex conditions that often require…Predicting Alpha-Synuclein Pathology by REM Sleep Behavior Disorder Diagnosis
Objective: Determine sensitivity, specificity and predictive value of clinician diagnosed probable REM sleep behavior disorder (PRBD) in predicting alpha-synuclein pathology. Background: Inability to accurately diagnose…Improving compliance to Parkinsonism’s pharmacotherapy amongst patients attending a Movement Disorders Clinic (MDC)
Objective: To improve patients’ compliance with Parkinsonism's pharmacotherapy to achieve more accurate clinical assessment in an outpatient setting. Background: Patients with Parkinsonism are encouraged to…Serum fractalkine levels in Parkinson’s disease: Evidence for neuroinflammation
Objective: Parkinson's disease (PD) is a debilitating neurodegenerative disorder characterized by loss of dopamine neurons in the substantia nigra. We measured neuroinflammatory marker fractalkine in…Patient Perspective in Multiple System Atrophy
Objective: To report patient and/ or caregiver perspective in Multiple System Atrophy (MSA). Background: The majority of literature on MSA’s natural history comes from single…Revision of Parkinson’s disease diagnosis during a long-term follow-up
Objective: The aim of this work was to describe the features of patients with an incorrect diagnosis of Parkinson’s disease (PD) during a long-term clinical…
- « Previous Page
- 1
- …
- 248
- 249
- 250
- 251
- 252
- …
- 405
- Next Page »